VAUGHAN, ON, March 12, 2015 /CNW/ - CannTrust, Canada's only pharmacist-controlled licensed producer and distributor of medical cannabis today announced a collaboration with Canabo Medical Corporation (Canabo) to partner on a research project on marijuana for medical purposes.
Canabo is a leader in patient care for cannabinoids and medical marijuana and will oversee the research through its network of healthcare practitioners at its medical clinics over the next 24 months.
"By capturing and examining real-world data, the outcome goal of the research aims to provide insights into the effects of various strains and its impact to treat a range of chronic conditions," says JC St-Amour, Chief Executive Officer of Canabo. "Data collected will be useful to clinicians, policy makers, patient groups, and the licensed producers involved in the growing and distribution of medical cannabis as a therapeutic modality".
Evidence-based medicine in combination with expert medical advice provides patients with a targeted approach to using medical cannabis in the management of various conditions that have negative health impacts on the patient and their quality of life.
"At CannTrust, patients are our first priority," says Norman Paul, Chairman of CannTrust. "Through the Canabo collaborative research project, we're contributing to the growing body of evidence-based research for the use and efficacy of medical cannabis and, importantly, will be helping our patients to better manage their medical conditions."
About Canabo Medical Corporation
Canabo Medical Corporation is at the forefront of patient care in the field of prescription cannabinoids and medical marijuana. Its referral-only clinics incorporate evidence-based medicine in combination with expert opinion to provide a safe approach to treating the needs of patients suffering from chronic and disabling illnesses to improve their quality of life. Canabo staff are dedicated to helping patients find effective treatment for chronic and serious conditions through the use of prescription cannabinoids and herbal cannabis, educating patients, physicians and the community and advancing research in the field of cannabinoids.
About CannTrust Inc.
CannTrust received its license to distribute medical cannabis to patients who have a completed medical document from their physician in February 2015 and is currently offering 6 highly acclaimed strains of hydroponically grown pharmaceutical-grade cannabis.
Based in Vaughan, Ontario, CannTrust is committed to producing the highest quality pharmaceutical-grade medical cannabis; promoting evidence based clinical research; and providing exceptional customer support. To do so, CannTrust has invested in its state-of-art hydroponic facility and onsite laboratory equipped with leading-edge technology, and has an exceptional team of pharmacists, nurses, scientists, laboratory technicians, master growers and call centre specialists.
The company places a focus on patient education about medical cannabis across Canada through partnerships with a variety of patient and physician-based organizations such as the Canadian Cancer Survivor Network, FORCES & FAMILIES, Canadian Consortium for the Investigation of Cannabinoids among others and provides the most comprehensive patient assistance program for patients with financial needs in Canada.
For more information, visit CannTrust.ca or call 1-855-RX4-CANN (794-2266).
SOURCE CannTrust Inc.
For further information: Tova Manett, CannTrust Inc., firstname.lastname@example.org, 647-872-2305; JC St-Amour, Canabo Medical Corporation, email@example.com, 647-296-9871